Extent of Left Ventricular Scar Predicts Outcomes in Ischemic Cardiomyopathy Patients With Significantly Reduced Systolic FunctionA Delayed Hyperenhancement Cardiac Magnetic Resonance Study
Deborah H. Kwon, MD*,
Carmel M. Halley, MD*,
Thomas P. Carrigan, MD ,
Victoria Zysek, DO ,
Zoran B. Popovic, MD, PhD*,
Randolph Setser, PhD ,
Paul Schoenhagen, MD*, ,
Randall C. Starling, MD, MPH*,
Scott D. Flamm, MD*, ,
Milind Y. Desai, MD*, ,*
* Department Cardiovascular Medicine, Cleveland, Ohio
Department of Internal Medicine, Cleveland, Ohio
Department of Radiology, Cleveland Clinic, Cleveland, Ohio
* Reprint requests and correspondence: Dr. Milind Y. Desai, Department of Cardiovascular Medicine, Desk F 15, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195 (Email: desaim2{at}ccf.org).
Objectives: The objective of the study was to determine whether the extent of left ventricular scar, measured with delayed hyperenhancement cardiac magnetic resonance (DHE-CMR), predicts survival in patients with ischemic cardiomyopathy (ICM) and severely reduced left ventricular ejection fraction (LVEF).
Background: Patients with ICM and reduced LVEF have poor survival. Such patients have a high myocardial scar burden. CMR is highly accurate in delineation of myocardial scar.
Methods: We studied 349 patients (76% men) with severe ICM ( 70% disease in 1 epicardial coronary, and mean LVEF of 24%) that underwent DHE-CMR (Siemens 1.5-T scanner, Erlangen, Germany), between 2003 and 2006. Scar (quantified as percentage of myocardium) was defined on DHE-MR images as an intensity >2 standard deviations above the viable myocardium. Transmurality score was semiquantitatively recorded in a 17-segment model as: 0 = no scar, 1 = 1% to 25% scar, 2 = 26% to 50%, 3 = 51% to 75%, and 4 = >75%. The LVEF, demographic data, risk factors, need for cardiac transplantation (CTx), and all-cause mortality were recorded.
Results: The mean age and follow-up were 65 ± 11 years and 2.6 ± 1.2 years (median 2.4 years [1.1, 3.5]), respectively. There were 56 events (51 deaths and 5 CTx). Mean scar percentage and transmurality score were higher in patients with events versus those without (39 ± 22 vs. 30 ± 20, p = 0.003, and 9.7 ± 5 vs. 7.8 ± 5, p = 0.004). On Cox proportional hazard survival analysis, quantified scar was greater than the median (30% of total myocardium), and female gender predicted events (relative risk 1.75 [95% Confidence Interval: 1.02 to 3.03] and relative risk 1.83 [95% Confidence Interval: 1.06 to 3.16], respectively, both p = 0.03).
Conclusions: In patients with ICM and severely reduced LVEF, a greater extent of myocardial scar, delineated by DHE-CMR is associated with increased mortality or the need for cardiac transplantation, potentially aiding further risk-stratification.
Key Words: delayed hyperenhancement CMR and outcomes ischemic cardiomyopathy
|
Abbreviations and Acronyms
| | ACE-I = angiotensin-converting enzyme inhibitor | | bSSFP = balanced steady-state free precession | | CAD = coronary artery disease | | CMR = cardiac magnetic resonance | | CTx = cardiac transplantation | | DHE-CMR = delayed hyperenhancement cardiac magnetic resonance | | ICD = implantable cardioverter defibrillator | | ICM = ischemic cardiomyopathy |
|
Related Article
-
Can Cardiac Magnetic Resonance Myocardial Scar Features Affect Treatment Decisions for Patients With Coronary Artery Disease and Heart Failure?
- Raymond Y. Kwong
J. Am. Coll. Cardiol. Img. 2009 2: 45-47.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
D. H. Kwon, N. G. Smedira, E. R. Rodriguez, C. Tan, R. Setser, M. Thamilarasan, B. W. Lytle, H. M. Lever, and M. Y. Desai
Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia.
J. Am. Coll. Cardiol.,
July 14, 2009;
54(3):
242 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Desai and S. D. Flamm
End of the Road for Delayed Hyperenhancement Cardiac Magnetic Resonance?
J. Am. Coll. Cardiol. Img.,
April 1, 2009;
2(4):
421 - 423.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Y. Kwong
Can cardiac magnetic resonance myocardial scar features affect treatment decisions for patients with coronary artery disease and heart failure?
J. Am. Coll. Cardiol. Img.,
January 1, 2009;
2(1):
45 - 47.
[Full Text]
[PDF]
|
 |
|
|